HomeAI · summaries
Storia in 17 fonti
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
Novo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that…
- ·
statnews.com
Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
Novo Nordisk sued Eli Lilly for allegedly running a “deceptive” ad campaign that uses “outdated clinical trials” to make its obesity and diabetes drugs appear more effective.
